Multiple Sclerosis Resource Centre

Welcome to the Multiple Sclerosis Resource Centre. This website is intended for international healthcare professionals with an interest in Multiple Sclerosis. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

The Importance of Lipids in MS (CMSC 2016)

A presentation at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), held June 1-4 in National Harbor, MD, demonstrated the important of lipids for the brain in MS. Lipids are important for the myelin sheath, and minimize signaling speed through nerve cells, and reduce the energy requirements for transmitting signals. Lipids contribute to protein transport, and are important components of neurotransmitters. Additionally, lipids are important activators and chemotactic molecules for the immune system, explained John Nieland, PhD, Aalborg University, Aalborg, DK.

Lipids bind to immunogenic sites in a protein, prevent post-translational modification, and prevent immunogenic proteins of the myelin sheath from being detected by B and T cells. Although lipids bound to the myelin sheath have a half-life of only 3 days.

Under conditions of stress (pathological, physiological, and psychological), a state of local hypoxia can occur and shift metabolism from normal glucose metabolism to lipid metabolism. When lipid levels are reduced, this prevents lipidation of the myelin sheath, and leads to downstream effects that leave the myelin sheath vulnerable to inflammatory attack. By focusing treatment on the inflammatory attack, this may only be treating a symptom of the disease.

Angelique Corthals, PhD, Stony Brook Medicine, Stony Brook, NY, explained that the immune system may only be part of the pathological progression of MS. White matter in patients with MS has structural abnormalities in lipids, and serum lipids show these alterations as well. These structural abnormalities cannot be detected with standard clinical laboratory tests.

The endogenous pathway for lipid metabolism plays an important role in CNS myelination. Peroxisome proliferator activated receptors (PPARS) are at the center of the regulation between lipid metabolism and immune system homeostasis. PPARS regulate key enzymes involved in lipid metabolism and the acute-phase response of the immune system. Dr. Corthals proposed that MS pathogenesis may originate in a dysregulation of lipid homeostasis through faulty PPAR genes and environmental triggers, such as diet and pathogens, that accentuate a dysregulatory loop.

A diet high in fat and carbohydrates compounded with environmental factors, and genetic factors linked to PPAR regulatory functions in lipid homeostasis and the immune system may represent increased risk for certain populations to develop MS. A symptom-by-symptom approach will not be successful in treating MS under these circumstances. However, rebalancing homeostasis in both lipid metabolism and the immune system, may be effective. Dr. Corthals concluded that to fully understand the influence of PPARS on MS and potential therapeutic options will take much more work to understand.

Ann Skottrup Morkholt, PhD, Aalborg University, Aalborg, DK, discussed a therapeutic target of lipid metabolism that is under investigation in preclinical models. CPT-1 is an important component in beta-oxidation, inhibition of CPT-1 can block lipid metabolism and can influence the development of MS. Blocking of CPT-1 completely blocks mitochondrial lipid metabolism.

Etomoxir (MIQ-001) blocks CPT-1, which leads to inhibition of lipid metabolism and the inflammatory response. In a preclinical model of MS (intradermal injection of myelin oligodendrocyte glycoprotein (MOG35-55), etomoxir reduced the severity of MS symptoms and restored neural functioning in more than 50% of mice. In a comparison study with interferon-β, etomoxir was significantly better for reducing disease score compared with interferon-β and placebo on days 1 and 5 after disease induction. Given the success in preclinical models, the researchers plan to conduct clinical trials in MS patients with secondary progressive MS and acute optic neuritis.


Search this site

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in MS research sign up to our e-alert.

Subscribe »

About the Editors

  • Prof Timothy Vartanian

    dsc_0787_400x400.jpg Timothy Vartanian, Professor at the Brain and Mind Research Institute and the Department of Neurology, Weill Cornell Medical College,...
  • Dr Claire S. Riley

    headshotcsr1_185x250.jpg Claire S. Riley, MD is an assistant attending neurologist and assistant professor of neurology in the Neurological Institute, Columbia...
  • Dr Rebecca Farber

    picforelsevier.jpg Rebecca Farber, MD is an attending neurologist and assistant professor of neurology at the Neurological Institute, Columbia University, in...

This online Resource Centre has been made possible by a donation from EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany.

Note that EMD Serono, Inc., has no editorial control or influence over the content of this Resource Centre. The Resource Centre and all content therein are subject to an independent editorial review.

The Grant for Multiple Sclerosis Innovation
supports promising translational research projects by academic researchers to improve understanding of multiple sclerosis (MS) for the ultimate benefit of patients.  For full information and application details, please click here

Journal Editor's choice

Recommended by Prof. Brenda Banwell

Causes of death among persons with multiple sclerosis

Gary R. Cutter, Jeffrey Zimmerman, Amber R. Salter, et al.

Multiple Sclerosis and Related Disorders, September 2015, Vol 4 Issue 5